You're contacting media contact of this press release
Title: Chief Medical Correspondent Ranks CoreAge Rx #1 Among GLP-1 Telehealth Providers, Awarding 9.5/10 for Specialist Care and Comprehensive Patient Support
United States, 27th Feb 2026 - Chief Medical Correspondent, an evidence-based medical review platform, has ranked CoreAge Rx first among the top five GLP-1 telehealth providers in its comprehensive Semaglutide program analysis. The full review is available at www.chiefmedicalcorrespondent.com/blog/coreage-rx-semaglutide-reviews. The platform awarded CoreAge Rx a 9.5 out of 10 rating, placing it above competitors including Henry Meds, Hims & Hers, Ro, and Noom Med across criteria that included medical team credentials, care personalization, pricing transparency, and patient support quality.Chief Medical Correspondent highlighted CoreAge Rx's use of board-certified endocrinologists and obesity medicine physicians as its most defining feature. Unlike competing platforms that rely on general practitioners or rotating clinicians, CoreAge Rx assigns each patient the same physician throughout their treatment, enabling consistent oversight and more informed dosing decisions over time. Prescription approvals are processed the same day for qualified patients, and each member is assigned a dedicated care coordinator who serves as a direct liaison between the patient and the medical team.The platform noted that CoreAge Rx includes monthly metabolic panel monitoring as part of its program — a service that typically costs patients $100 to $200 elsewhere. The program starts at $99 per month, with compounded Semaglutide priced separately based on dose level. Chief Medical Correspondent noted that while this positions CoreAge Rx at a higher price point than basic telehealth alternatives, the included services — specialist access, dedicated coordinator, and lab monitoring — represent concrete value rather than marketing differentiation."Every patient deserves a physician who actually...
This press release is issued by King Newswire